tiprankstipranks
Trending News
More News >
Penumbra (PEN)
NYSE:PEN
US Market
Advertisement

Penumbra (PEN) Earnings Dates, Call Summary & Reports

Compare
450 Followers

Earnings Data

Report Date
Oct 29, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
0.92
Last Year’s EPS
0.85
Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 29, 2025|
% Change Since: 6.98%|
Earnings Call Sentiment|Positive
Penumbra's earnings call reflected strong revenue growth and successful execution in the thrombectomy business, particularly in the U.S., with positive clinical trial developments. However, challenges in international markets, particularly in China, and operating margin variability due to strategic investments posed some concerns.
Company Guidance -
Q3 2025
During Penumbra's second quarter 2025 earnings call, the company provided updated guidance due to its strong performance, raising its total revenue forecast to a range of $1.355 billion to $1.370 billion, reflecting a year-over-year growth of 13% to 15%. The U.S. thrombectomy business is expected to grow by 20% to 21% compared to 2024. Penumbra reported total revenue of $339.5 million for the second quarter, a 13.4% increase on a reported basis and 12.7% on a constant currency basis from the previous year. U.S. thrombectomy revenue grew 22.6% year-over-year to $188.5 million, driven by a 42% increase in the U.S. VTE franchise. The company's gross margin was 66%, with expectations to exceed 70% by the end of 2026. Operating income reached $40.8 million or 12% of revenue, a significant improvement from a loss of $1.6 million in the same period last year. Adjusted EBITDA was $61.4 million, representing 18.1% of total revenue, up from $13 million or 4.3% in the second quarter of the previous year.
Strong Revenue Growth
Penumbra reported total revenue of $339.5 million for Q2 2025, representing a 13.4% year-over-year growth on a reported basis and 12.7% on a constant currency basis.
U.S. Thrombectomy Business Success
The U.S. thrombectomy business increased by 22.6% year-over-year to $188.5 million, with the U.S. VTE franchise growing by 42% year-over-year.
Gross Margin Improvement
The gross margin for Q2 2025 was 66%, up from 54.4% in Q2 2024, excluding a one-time inventory write-off.
Positive Clinical Trial Enrollment
Enrollment in the STORM-PE trial was completed ahead of schedule, with results expected to be presented at a major medical conference in the fall.
Increased Full-Year Revenue Guidance
Total revenue guidance for 2025 was increased to a range of $1.355 billion to $1.370 billion, representing 13% to 15% year-over-year growth.

Penumbra (PEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 29, 2025
2025 (Q3)
0.92 / -
0.85
Jul 29, 2025
2025 (Q2)
0.82 / 0.86
0.6434.37% (+0.22)
Apr 23, 2025
2025 (Q1)
0.67 / 0.83
0.41102.44% (+0.42)
Feb 18, 2025
2024 (Q4)
0.90 / 0.97
0.7627.63% (+0.21)
Oct 30, 2024
2024 (Q3)
0.69 / 0.85
0.6726.87% (+0.18)
Jul 30, 2024
2024 (Q2)
0.56 / 0.64
0.4348.84% (+0.21)
May 07, 2024
2024 (Q1)
0.39 / 0.41
0.2378.26% (+0.18)
Feb 22, 2024
2023 (Q4)
0.70 / 0.76
0.16375.00% (+0.60)
Nov 02, 2023
2023 (Q3)
0.45 / 0.67
0.016600.00% (+0.66)
Aug 01, 2023
2023 (Q2)
0.28 / 0.43
0.014200.00% (+0.42)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 29, 2025
$227.15$254.21+11.91%
Apr 23, 2025
$278.77$298.25+6.99%
Feb 18, 2025
$271.14$303.76+12.03%
Oct 30, 2024
$211.29$228.87+8.32%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Penumbra (PEN) report earnings?
Penumbra (PEN) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).
    What is Penumbra (PEN) earnings time?
    Penumbra (PEN) earnings time is at Oct 29, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PEN EPS forecast?
          PEN EPS forecast for the fiscal quarter 2025 (Q3) is 0.92.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis